MTRIMTRIHealthcare · Drug Manufacturers - Specialty & Generic

MTRI Stock Forecast: Mentari Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 6 Nov 2026
$16
+17.79% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 7 Nov 2026 — in the lower half.

Market cap
$8.5M
Ticker Nerd rank
27/ 100
Median analyst target
—
Analysts covering
0
Revenue$0.0−100.0% y/y
Operating income−$3.2M
Net income−$5.8M
Free cash flow−$3.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.7%
1M
+17.0%
YTD
+46.8%
1Y
−8.7%
From 52W high
−15.9%
From 52W low
+153.0%
$6
$19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MTRI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Mentari Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Nov 2026
27/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Size
92
Issuance
60
Momentum
45
Growth
31
Revisions
25
Quality
7
Volatility
4
Value
4

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (4): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MTRI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MTRI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$6$8$10$12$14$16$18Jan 26Apr 26Jul 26Oct 26MTRI

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 Dec 2021HC Wainwright & Co.InitiatesBuy—
29 Nov 2021HC Wainwright & Co.InitiatesBuy—
16 Feb 2021Roth CapitalMaintainsBuy$12 → $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

MTRI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MTRI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Nov 2026, Mentari Therapeutics, Inc. returned −8.7% against +10.9% for the S&P 500, dividends included.

MTRI vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26MTRIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MTRI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Mentari Therapeutics, Inc. (MTRI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
1.4×

Cheaper than 59% of US stocks

Price / book
8.4×

Cheaper than 10% of US stocks

EV / EBITDA
−8.5×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
0.0%

Higher than 31% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−222.1%

Higher than 7% of US stocks

Return on assets
−85.6%

Higher than 4% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Mentari Therapeutics, Inc. (MTRI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Mentari Therapeutics, Inc. has a market value of $8.5M and an enterprise value of $84.3M.

  • Revenue in the twelve months to 30 June 2026: $1.9M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$12.6M, a −647.4% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$8.6M.

  • Shares outstanding: 5.3M.

  • Trailing P/E: 0.0×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Mentari Therapeutics, Inc. employs 6 people — $323K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Nov 2026

Data provided by Twelve Data

Peers

MTRI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
MTRIMentari Therapeutics, Inc.$8.5M27
UPCUniverse Pharmaceuticals, Inc.$7.0M27
BFRIBiofrontera, Inc.$12.3M66
SNOASonoma Pharmaceuticals, Inc.$5.3M35
GELSGelteq Ltd.$4.7M11
YCBDcbdMD, Inc.$4.7M26
APUSApimeds Pharmaceuticals US, Inc.$4.1M10

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Mentari Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MTRI news & analysis

Mentari Therapeutics to Present at Upcoming Investor Conferences

GlobeNewsWire · 9 Nov 2026neutral

Mentari Therapeutics announced that members of its management team will participate in investor conferences in November. The company is a clinical-stage biotechnology company developing therapies for migraine prevention.

Why it matters — The appearances provide MTRI watchers with opportunities to hear from company management.

InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics

PRNewsWire · 6 Nov 2026neutral

InMed Pharmaceuticals announced that it completed its merger with privately held Mentari Therapeutics and changed its name to Mentari Therapeutics, Inc. The combined company is expected to begin Nasdaq trading as MTRI on November 9, 2026.

Why it matters — INM watchers should note the company’s name and ticker are changing following the merger.

InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI"

Newsfile Corp · 5 Nov 2026neutral

InMed said its merger with Mentari Therapeutics is expected to close on November 6, 2026, subject to remaining closing conditions. Before the merger is completed, the company expects to redomesticate from British Columbia to Nevada; the headline says trading is expected under the Mentari name and ticker MTRI.

Why it matters — INM watchers should note the anticipated merger closing, corporate redomestication, and change in company name and Nasdaq ticker.

InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation

Newsfile Corp · 4 Nov 2026neutral

InMed Pharmaceuticals reported that shareholders voted on the matters presented at its 2026 annual general and special meeting. The company is now Mentari Therapeutics, Inc.; the excerpt does not specify the vote outcomes or details of the share consolidation.

Why it matters — INM watchers may note the company’s announced name change and that meeting matters were put to a shareholder vote, while the excerpt provides no specific results.

InMed Reports First Quarter Fiscal 2027 Financial Results and Provides Corporate Update

Newsfile Corp · 3 Nov 2026neutral

InMed Pharmaceuticals reported financial results for the first quarter of fiscal 2027, ended September 30, 2026, and provided a corporate update. The company said its full financial statements and related MD&A are available on its website and regulatory filing sites.

Why it matters — INM watchers can review the company’s quarterly financial statements and management discussion for details on its results and corporate update.

FAQ

Frequently asked questions about MTRI stock

How does Ticker Nerd's model rank MTRI?

As at 7 Nov 2026, Mentari Therapeutics, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

What is the MTRI stock forecast for 2030?

No analyst covering Mentari Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MTRI are extrapolating price history, which says nothing about the business.

How has MTRI stock performed over the past year?

Mentari Therapeutics, Inc. returned -8.7% over the 12 months to 6 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Mentari Therapeutics, Inc. do?

InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing cannabinoid-based small molecule therapies and pharmaceutical-grade cannabinoid manufacturing technologies.

What is the latest news on MTRI?

The most recent item we track (GlobeNewsWire, 9 Nov 2026): "Mentari Therapeutics to Present at Upcoming Investor Conferences". Mentari Therapeutics announced that members of its management team will participate in investor conferences in November. The company is a clinical-stage biotechnology company developing therapies for migraine prevention.

Company

About Mentari Therapeutics, Inc.

InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing cannabinoid-based small molecule therapies and pharmaceutical-grade cannabinoid manufacturing technologies. The company’s current work centers on research and development programs targeting Alzheimer’s disease, ocular disorders, and dermatological conditions, including epidermolysis bullosa and glaucoma. InMed Pharmaceuticals also operates a commercial segment through BayMedica, which develops proprietary methods to produce and commercialize rare cannabinoids for use in health and wellness products and other ingredient markets. Its pipeline includes specialized product candidates and manufacturing platforms designed to support both therapeutic development and cannabinoid supply. Headquartered in Vancouver, Canada, InMed Pharmaceuticals plays a niche role in the biotechnology sector by combining drug discovery with cannabinoid-focused production capabilities.

CEO Mr. Eric A. Adams B.S. Chem., M.I.B. · 6 employees · Canada · https://www.inmedpharma.com